$ADMA Legal Notice: ADMA Biologics Sued on Behalf of Investors Over Misstatements Tied to Channel Stuffing Allegations
Bleichmar Fonti & Auld LLP announced a class action lawsuit against ADMA Biologics alleging securities fraud related to a channel stuffing scheme and misstated revenue growth. The litigation follows a March 24, 2026 report by Culper Research which claimed ADMA's reported 20% growth was inflated, triggering a 16.6% drop in the stock price. Investors have until August 10, 2026 to seek appointment as lead plaintiff in the pending case within the U.S.
Key figures
- Case number
- 26-cv-6918
- Lead plaintiff deadline
- August 10, 2026
- Mar 24 2026 stock drop percent
- 16.6%
- Alleged channel stuffing growth delta
- 23%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.